Aelis FarmaFRA:69O -0.58%32 Quick Ratio is 4.40 as of Dec. 2025, which is 20% above its 10-year median of 3.66. GuruFocus rates FRA:69O with a GF Score™ of 32/100 and a GF Value™ of €0.95. The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, Aelis Farma ranks better than 55.89% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aelis Farma's quick ratio for the quarter that ended in Dec. 2025 was 4.40.
Aelis Farma has a quick ratio of 4.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for Aelis Farma's Quick Ratio or its related term are showing as below:
FRA:69O'
s Quick Ratio Range Over the Past 10 Years
Min: 1.97 Med: 3.66 Max: 5.53
Current: 4.4
During the past 9 years, Aelis Farma's highest Quick Ratio was 5.53. The lowest was 1.97. And the median was 3.66.
FRA:69O's Quick Ratio is ranked better than 55.89% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs FRA:69O: 4.40
Aelis Farma (FRA:69O) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aelis Farma Quick Ratio Related Terms
Aelis Farma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Aelis Farma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:69O vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Aelis Farma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aelis Farma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aelis Farma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aelis Farma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Aelis Farma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aelis Farma (FRA:69O) has a Quick Ratio of 4.40 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aelis Farma and its competitors. This is 20% above median its historical median of 3.66. Over the past decade, Aelis Farma's Quick Ratio has ranged from 1.97 to 5.53. According to the industry distribution chart, Aelis Farma ranks #622 out of 1410 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Aelis Farma's Quick Ratio too high?
Aelis Farma's current Quick Ratio of 4.40 is 20% above median its 10-year median of 3.66. Over the past 10 years, this metric has ranged from a low of 1.97 to a high of 5.53. The Biotechnology industry median Quick Ratio is 3.60. Aelis Farma's value of 4.40 is 22.2% above this industry median. Based on the distribution chart, Aelis Farma ranks #622 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aelis Farma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Aelis Farma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aelis Farma ranks #622 out of 1410 companies for Quick Ratio. This puts Aelis Farma in the upper half of its industry. The industry median Quick Ratio is 3.60. Aelis Farma's value of 4.40 is 22.2% above this benchmark. Historically, Aelis Farma's own Quick Ratio has ranged from 1.97 to 5.53 over the past decade. While the company's 10-year median is 3.66 vs. the industry median of 3.60, Aelis Farma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aelis Farma's current Quick Ratio of 4.40 is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aelis Farma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aelis Farma's current Quick Ratio is 4.40, which is 20% above median its own 10-year median of 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aelis Farma stock overvalued right now?
Aelis Farma (FRA:69O) has a current Quick Ratio of 4.40. The stock's GF Value™ is €0.95, compared to a current price of €1.03 — trading 8.4% above its estimated fair value. The current Quick Ratio is 4.40, which is 20% above median its 10-year median of 3.66 and 22.2% above the Biotechnology industry median of 3.60. Aelis Farma's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Aelis Farma (FRA:69O), the current Quick Ratio is 4.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aelis Farma (FRA:69O) Overvalued in 2026?
Based on GuruFocus' analysis, Aelis Farma stock appears to be overvalued.
The current stock price of €1.03 is trading 8.4% above its estimated GF Value™ of €0.95.
Key valuation signals for FRA:69O:
Quick Ratio: 4.40 (20% above median its 10-year median of 3.66)
GF Value™: €0.95 vs. price of €1.03 (8.4% above fair value)
Industry Position: 22.2% above the Biotechnology median (#622 of 1410)
No single metric tells the full story. See the FRA:69O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases. The Company operates in only one business segment: the research and development of pharmaceutical products.
32GF Score
Get the complete analysis for FRA:69O
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:69O has been successfully added to your 
